Introduction: COVID-19 is a highly contagious respiratory disease and many factors can affect its severity and mortality. This study aimed to investigate the risk factors associated with the severity and mortality of COVID-19.
Methods: In this study, 311 cases with COVID-19 approved by the CORONA database in the Center for Disease Control and Prevention (CDC) of Shiraz University of Medical Sciences were selected using a random systematic sampling method. The study data were collected through interviews and phone calls.
Results: The mean age of the participants was 45.82±17.92 years, and the male to female ratio was 1.57:1. In addition, the Case Fatality Rate (CFR) was 4.50%, and the disease was severe in 47.5% of the cases. The most common clinical symptoms were cough (39.22%), fever (31.83%), and dyspnea (24.76%). The severity of COVID-19 was significantly associated with age and history of Cardiovascular Disease (CVD). Besides, the mortality of COVID-19 was significantly related to age, gender, hypertension, CVD, and Chronic Kidney Disease (CKD). The mean interval between the onset of the first symptom and referral to health center was 3.02±2.82 days. Additionally, the mean interval between the referral to health centers and testing was 0.88±2.20 days.
Conclusion: Older patients and those who had CVD needed more careful healthcare and early intervention to prevent the exacerbation of COVID-19. Furthermore, the interval between the onset of the first symptom and testing was relatively long. Overall, early diagnosis, isolation, and treatment of patients were found to be essential to control COVID-19.
1. WHO. Coronavirus Disease 2019 (COVID-19) Outbreak. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (18 February 2020, date last accessed).
2. Chen, L., et al., Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases, 2020. 20(4): p. 398-400.
3. Lipsitch, M., D.L. Swerdlow, and L. Finelli, Defining the epidemiology of Covid-19—studies needed. New England journal of medicine, 2020. 382(13): p. 1194-1196.
4. Wang, C., et al., A novel coronavirus outbreak of global health concern. The Lancet, 2020. 395(10223): p. 470-473.
5. Alimohamadi, Y., et al., The estimate of the basic reproduction number for novel coronavirus disease (COVID-19): a systematic review and meta-analysis. 2020.
6. Rodriguez-Morales, A.J., et al., Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel medicine and infectious disease, 2020: p. 101623.
7. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020. 395(10223): p. 507-513.
8. Zhou, F., et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 2020.
9. To, K.K.-W., et al., Consistent detection of 2019 novel coronavirus in saliva. Clinical Infectious Diseases, 2020.
10. Hui, D.S., et al., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 2020. 91: p. 264-266.
11. Yu, C., et al., Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China. 2020.
12. Cen, Y., et al., Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019da multi-centre observational study. 2020.
13. Oyelade, T., et al., Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. 2020. 5(2): p. 80.
14. Grasselli, G., et al., Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. 2020. 180(10): p. 1345-1355.
15. Li, T., et al., Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. 2020. 91: p. 104185.
16. Metlay, J.P., et al., Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. 2019. 200(7): p. e45-e67.
17. Shahriarirad, R., et al., Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. 2020. 20(1): p. 1-12.
18. Nikpouraghdam, M., et al., Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. 2020.
19. Anderson, R.M., et al., How will country-based mitigation measures influence the course of the COVID-19 epidemic? 2020. 395(10228): p. 931-934.
20. Rodriguez-Morales, A.J., et al., Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. 2020: p. 101623.
21. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 2020. 395(10223): p. 497-506.
22. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. 2020. 395(10223): p. 507-513.
23. Zhao, S., et al., Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. 2020. 92: p. 214-217.
24. Wu, C., et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. 2020.
25. Guan, W.-j., et al., Clinical characteristics of coronavirus disease 2019 in China. 2020. 382(18): p. 1708-1720.
26. Ssentongo, P., et al., Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. 2020. 15(8): p. e0238215.
27. Yusuf, S., et al., Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. 2020. 395(10226): p. 795-808.
28. Lippi, G., J. Wong, and B.M.J.P.A.I.M. Henry, Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. 2020. 130(4): p. 304-309.
29. D’Marco, L., et al., Coronavirus disease 2019 in chronic kidney disease. 2020. 13(3): p. 297-306.
30. Soares, R.d.C.M., et al., Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo State, Brazil. 2020. 103(3): p. 1184-1190.
31. Li, X., et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. 2020.
32. Li, K., et al., The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. 2020.